Strong Revenue Growth
Total revenue for Q3 2025 was $384.2 million, up 13% year-over-year on a GAAP basis and 12.5% on a constant currency basis, exceeding expectations.
Improvement in Operating Margin
Non-GAAP operating margin increased 51 basis points year-over-year to 19.7%, with nearly 7% growth in non-GAAP EPS.
Record Gross Margin
Gross margin was 53.6%, up 267 basis points year-over-year, representing the highest gross margin in the company's history.
Free Cash Flow Increase
The company generated $53 million of free cash flow in Q3, an increase of 38% year-over-year.
Product Innovation and Commercialization
Introduction of Prelude Wave hydrophilic sheath introducer and CE Mark received for Embosphere Microspheres for knee osteoarthritis treatment.
Strategic Acquisition
Agreement to acquire C2 CryoBalloon technology from Pentax of America for $22 million to expand the gastroenterology market presence.